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Longitudinal Study of Recurrent Metastatic Melanoma
Cell Lines Underscores the Individuality of Cancer
Biology
Zoltan Pos1,2,3, Tara L. Spivey1,4,5, Hui Liu1, Michele Sommariva1,6, Jinguo Chen1, John R. Wunderlich7,
Giulia Parisi8, Sara Tomei9, Ben D. Ayotte10, David F. Stroncek11, Joel A. Malek9, Paul F. Robbins7,
Licia Rivoltini12, Michele Maio8, Lotfi Chouchane13, Ena Wang1 and Francesco M. Marincola1,14
Recurrent metastatic melanoma provides a unique opportunity to analyze disease evolution in metastatic cancer.
Here, we followed up eight patients with an unusually prolonged history of metastatic melanoma, who
developed a total of 26 recurrences over several years. Cell lines derived from each metastasis were analyzed
by comparative genomic hybridization and global transcript analysis. We observed that conserved, patient-
specific characteristics remain stable in recurrent metastatic melanoma even after years and several recurrences.
Differences among individual patients exceeded within-patient lesion variability, both at the DNA copy number
(Po0.001) and RNA gene expression level (Po0.001). Conserved patient-specific traits included expression of
several cancer/testis antigens and the c-kit proto-oncogene throughout multiple recurrences. Interestingly,
subsequent recurrences of different patients did not display consistent or convergent changes toward a more
aggressive disease phenotype. Finally, sequential recurrences of the same patient did not descend progressively
from each other, as irreversible mutations such as homozygous deletions were frequently not inherited from
previous metastases. This study suggests that the late evolution of metastatic melanoma, which markedly turns an
indolent disease into a lethal phase, is prone to preserve case-specific traits over multiple recurrences and occurs
through a series of random events that do not follow a consistent stepwise process.
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INTRODUCTION
Cancer progression is usually studied cross-sectionally, com-
paring lesions obtained from different patients, excised at
various stages. By combining these snapshots, the natural
history of the disease can be indirectly reconstructed. In
contrast, the preferable longitudinal analysis of sequential
lesions in the same patients is usually not feasible, especially
difficult to perform in rapidly progressing cancers, such as
melanoma, and particularly challenging when analyzing
disease progression in metastases (Bonsing et al., 1993;
Kuukasjarvi et al., 1997; Navin et al., 2011).
However, the limited number of such longitudinal studies
leaves several questions open. First, cross-sectional studies do
not allow an estimate of the extent to which patient-specific
traits remain stable over time. Therefore, it is difficult to assess
the stability of such patient-specific traits over time, which is a
question of basic importance in personalized cancer therapy
(Gupta et al., 2009; Harbst et al., 2010; Navin et al., 2010).
In addition, with cross-sectional analyses, it is impossible to
test whether late disease development follows a pattern of
sequential somatic microevolution or whether subsequent
metastases represent individual buddings from a stable set of
cancer progenitors, creating independently established new
metastatic lesions (Wang et al., 2006; Sabatino et al., 2008).
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Finally, it is difficult to quantify whether sequential steps are
involved in late-stage progression, and to estimate whether
consistent changes are required for the late progression of
melanoma from a metastatic phase that progresses slowly to a
rapid evolution in the declining phase of one patient’s life.
By studying longitudinally several recurrent melanoma
metastases of a rare collection of eight individuals who
developed multiple recurrences over a period of years (see
Supplementary Table S1 online), we sought a better under-
standing of the above questions. This study is a follow-up from
a previous longitudinal study of a single case (Wang et al.,
2006; Sabatino et al., 2008) focusing on traits remaining stable
and changes repeated consistently among multiple developing
recurrent metastases of several melanoma patients. To our best
knowledge, these questions have not yet been analyzed by
others.
RESULTS
Long-term metastatic melanoma is consistent with canonical
melanoma genomics
As the cases with multiple recurrent metastases studied here
differ behaviorally from classic metastatic melanoma owing to
their unusually protracted course, we first evaluated whether
the cell lines derived from these unusual cases would differ
markedly from typical cases of melanoma, as published by
others.
Array comparative genomic hybridization (aCGH) con-
firmed that the chromosomal distribution of copy number
(CN) alterations (CNAs) prominently observed here are in line
with previous observations (Figure 1a) (Thompson et al., 1995;
Roschke et al., 2003; Jonsson et al., 2007; Spivey et al., 2012).
In addition, at the individual gene level, most genes were
affected by CN gains and losses in accordance with others’
reports (Okamoto et al., 1999; Pirker et al., 2003; Grafstrom
et al., 2005; Jonsson et al., 2007; Shi et al., 2012) (Figure 1b,
see full data set in Supplementary Table S2 online).
Finally, similar to others’ reports, we also found that a
correlation between CN and gene expression (GX) data are
present but limited in advanced cancer (Sabatino et al, 2008;
Spivey et al, 2012). Among 4,340 genes eligible for analysis,
2,766 correlated weakly (Pearson’s correlation Ro0.3,
Po0.05, false discovery rate (FDR) 0.05) and 272 correlated
strongly (Ro0.5, Po0.05, FDR 0.01) in CN and GX (see
Supplementary Figure S1 online).
Taken together, this data set was representative of typical
characteristics of metastatic melanoma genomics, as reported
in the literature (Thompson et al., 1995; Roschke et al., 2003;
Jonsson et al., 2007; Sabatino et al., 2008; ; Spivey et al.,
2012).
Advanced melanoma retains case-specific fingerprints after years
of disease progression
Following a rare case of metastatic melanoma that recurred
several times over a decade, we previously observed that in
spite of the stochastic and selective forces affecting its
genome, stable characteristics prevailed to the point that
recurrent lesions derived from this patient clustered away
from heterologous randomly collected cases (Wang et al.,
2006; Sabatino et al., 2008). This patient-specific stability, if
shared by other cases of advanced melanoma, could have
fundamental implications for personalized cancer therapy.
Thus, in this study, we first analyzed whether the previous
observations could be generalized to a larger set of patients.
First we compared CNA and GX patterns on a global
genomic scale among cell lines from the eight patients with
multiple recurrences. Multidimensional scaling (MDS), a
computational method enabling visualization of sample relat-
edness within large-scale genetic data, demonstrated that even
after years recurrent metastases of a given patient remained
closely related, keeping clear distance from others’ metastases
(Figure 2a and c). By comparing all metastases in all possible
pairs (325 pairs total), we found that MDS distances between
subsequent metastases (estimates of sample relatedness) of the
same patient were significantly shorter than those between
metastases of different patients (Figure 2b and d). This finding
held true whether CNA or GX data were compared.
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Figure 1. Description and basic characterization of the analyzed sample set
by integrated copy number and gene expression analysis. (a) Frequency and
spatial distribution of autosomal copy number (CN) aberrations in the analyzed
melanoma sample set. (b) Combined distribution analysis of CN gains and
losses affecting key melanoma genes, and also their distribution between
various disease-related biological functions, as defined by the Ingenuity
Pathway Analysis database. Selected key melanoma genes are labeled with
their respective HUGO gene symbols.
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Stable patient-specific traits include genes of relevance to
melanoma biology
We next searched for genomic aberrations typically specific to
a given patient. We found that stable case-specific CNAs
occurred in chromosomes 1, 5, 13, and 19 (Figure 3a; one-
way analysis of variance (ANOVA), Po0.05, FDRo0.001; see
Supplementary Table S3 online for details). Similarly, 925
genes were found to have stable, patient-specific expression;
61 among them could be categorized functionally as mela-
noma-related by the Ingenuity Pathway Analysis database
(Figure 3b; one-way ANOVA, Po0.05, FDRo0.05). The latter
included several genes with known tumorigenic properties
supporting autonomous proliferation (KIT,MYC, CDK2, RBL2),
controlling genomic stability (BRCA1), apoptosis and cell
survival (TP53BP2, CASP8, TEP1), adhesion and motility
(CDH1, ITGA4), invasiveness, matrix remodeling (MMP15,
MMP19), angiogenesis (ANGPT1, EGF), modulation of anti-
tumor immunity (large clusters of major histocompatibility
complex class I and II transcripts, the latter correlating with
CIITA expression), and several melanoma antigens (MAGE-A1,
-A4, -A9, -B2, -C2). This observation suggests that genes highly
relevant to melanoma progression retain stable patient-specific
expression levels over long periods of time (Figure 3b).
Notably, among all possible patient-to-patient comparisons
(28 pairwise comparisons involving 8 patients), 37 genes
demonstrated patient-specific expression patterns with signifi-
cant differences among patients and an at least 2-fold change
in470% of all pairwise comparisons. These includedMAGE-
A4, -B2, -C2, BAGE-2, and KIT (see Supplementary Table S4
online). To further test these results, we analyzed KIT protein
levels by flow cytometry in the investigated cell lines. Our
analysis disclosed that, although KIT expression is frequently
affected by post-transcriptional regulation, KIT protein levels
remain consistent throughout multiple recurrences of indivi-
dual patients, and whenever expressed they correlate well with
mRNA data (Supplementary Figure S2 online). Taken together,
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Figure 2. Comparison of the relative weights of within- versus between-patient differences in metastatic melanoma. (a)The whole complexity of DNA copy
number data reduced to three dimensions (D1–3) by multidimensional scaling (MDS). Metastases are symbolized by spheres. (A–H) Recurrent metastases
belonging to the same patient are color-coded; non-recurrent, random metastasis samples, serving as controls, are gray. (b) Distribution of MDS plot distances
between individual metastases representing the magnitude of actual genomic differences. Statistical comparisons of MDS distances (Bgenomic differences)
between recurrent metastases belonging to the same versus different patients are shown. P-values given are derived from a standard t-test considering all possible
recurrent metastasis pairs from the sample set. Panels c and d display similar information on whole-genome RNA expression data.
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these observations suggest that genes relevant to melanoma
immunology and melanoma cell biology are expressed stably
within a given patient, and may, in turn, be responsible for
behavioral differences among individual cancers.
Lack of evidence for convergent evolution and consistent
changes among patients over time
Next, we asked whether subsequent metastases from different
patients progressively converge to reach a terminal, potentially
lethal ‘‘hyperaggressive’’ status. This would imply that, on
average, early (e.g., first) metastases of individual patients
would be more different and more distant from each other
compared with late (e.g., the last) metastases of the same
individuals. MDS genomic distances demonstrate that this is
not the case (Figure 4a and b), neither at the CN nor at the GX
level.
To corroborate this finding, we next attempted to identify
consistent CN or GX changes that might represent a recurrent
theme in the transition from earlier to later metastases in a
given patient. However, statistical analysis was unable to
identify changes in CNAs or GX patterns that constitute
consistent trends in subsequent recurrences of metastatic
melanoma (two-way RM ANOVA, Po0.05, FDR 0.05). First,
an analysis of all recurrent metastases inclusive of patient
identity and lesion sequence revealed no consistent changes
between subsequent metastases. Next, as patients with large
numbers of recurrences dominate the analysis in such a
pairwise comparison, we decreased or eliminated differences
in per-patient sample sizes. To this end, we first replaced
multiple synchronous metastases with a single averaged value
for each parameter tested (Po0.05, FDR 0.05). In addition, in
a separate analysis, we limited the evaluated cases to three
randomly selected samples per patient (Po0.05, FDR 0.05).
No consistent changes were found by either analysis. Next,
assuming that the first and last available lesions in a given
patient were most distant genetically, we restricted the
analysis to these extreme pairs; but again, a pairwise analysis
including patient identity failed to identify statistically signifi-
cant differences (Po0.05, FDR 0.05). Finally, hypothesizing
that the last, supposedly most advanced, fatal lesion in a given
patient might be different from earlier ones, we compared the
latter with the former (Po0.05, FDR 0.05), again without
observing consistent differences. Taken together, no consistent
progression patterns could be observed between subsequent
metastases, either at the DNA CN or at RNA GX level,
regardless of the approach used for sample selection and
grouping before statistical analysis.
In line with this observation, comparison of the first
metastasis from a given patient with his subsequent ones
demonstrated that the latter are not necessarily drifting
progressively further from the original one (Figure 4c and d).
Rather, the data suggest a stochastic drift among subsequent
recurrent metastases.
We also tested whether multiple cycles of phenotype
switching between proposed invasive and proliferative phe-
notypes (Hoek et al., 2008) could explain a seemingly
stochastic drifting of recurrent melanoma metastases. We
found that this model may provide partial explanation for
our observations, as key genes of the two phenotypes were
expressed in an alternating manner, and the two phenotypes
seemed to change frequently back and forth through the
recurrences of most (e.g., patients B, C, D, F, G), although
certainly not all, patients (e.g., patients A and E,
Supplementary Figure S3 online).
The fate of homozygous deletions does not support cumulative
changes in the evolution of melanoma
As no stepwise evolutionary pattern could be discerned, we
next asked whether recurrent metastases from the same patient
descend sequentially from one another, i.e., if they acquire
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new mutations in a cumulative manner. To this end, we
followed up the fate of common BRAF and NRAS mutations
(Colombino et al., 2012) and homozygous deletions ( / ) in
subsequent recurrent metastases. Unfortunately, BRAF and
NRAS status turned out to be uninformative in this regard,
because as frequently observed in melanoma all recurrent
melanomas analyzed were BRAFV600E mutated and NRAS
wild type throughout (not shown). Next, we analyzed the fate
of homozygous deletions ( / ) that are thought to be
irreversible, as no known mechanisms for structural
restoration of these alterations have been described. On the
basis of this, we assumed that if subsequent recurrent
metastases of the same patient show reversions of
homozygous deletions, they cannot sequentially descend
from each other.
A total of 33 contiguous homozygous deletions were found
to affect the CDKN2A/CDKN2B region, various IFN genes,
B2M, major histocompatibility complex genes, etc. Out of
these, 25 deletions were eligible for analysis, as they emerged
in a metastasis for which there was at least a subsequent
metastasis to evaluate (Figure 5b). Out of 25 eligible homo-
zygous deletions, 15 (60%) appeared to be reverted in a given
patient’s disease history, suggesting that in subsequent metas-
tases of recurrent melanoma new mutations are not acquired
in a cumulative manner, and hence recurrent metastases do
not descend from each other (Figure 5b).
Recurrent melanomas show hints of slower growth, but more
frequent metastasis formation
In initial MDS analyses, cancer cells from patients with
recurrent long-term metastatic disease were hardly discernible
from those from sporadically excised, melanoma cases
(Figure 2a and c). Nevertheless, we identified a set of 177
genes differentially expressed between the two phenotypes,
which is a very small number compared with patient-to-
patient differences, eight of which were melanoma-related.
Interestingly, these genes hint to slower tumor growth
(retained CDKN1A and ANAPC expression), higher sensitivity
to immune- or therapy-mediated eradication (higher FAS but
lower levels of MGMT expression), and higher prometastatic
tendency (elevated levels of ALCAM; Supplementary Figure S4
online).
DISCUSSION
This study analyzes a specific time point in the natural history
of cancer when advanced disease of an indolent nature turns
into an aggressive and lethal stage. We studied the genetic
profile of melanoma cell lines derived from sequentially
excised metastases in unusual cases when the metastatic
process followed a protracted course. Although the use of
cell lines has significant limitations, we observed that early-
passage cell lines maintain stable genetic traits in vitro that
relate to the in vivo phenotype of parental tumors (Spivey
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et al., 2012). Nevertheless, our samples clearly do not equal
whole tumors, and these cases may have represented a special
subset of melanoma as well. First, these recurrent melanomas
displayed CDK2NA, PTEN, and BRAF CN aberrations
more frequently than average cases (Hodis et al., 2012;
Krauthammer et al., 2012). In addition, all 26 metastases of
the analyzed eight patients carried BRAFV600E, but displayed
wild-type NRAS. Conservation of BRAF mutation status across
metastases is in line with others’ observations (Niessner et al.,
2013). However, this particular BRAF/NRAS pattern is typical
for melanomas arising in intermittently sun-exposed areas
(Colombino et al., 2012), affects cell proliferation rate (Liu
et al., 2007), prognosis (Long et al., 2011), treatment of
choice, and, in this latter context, also BRAF CNs (Shi et al.,
2012).
Keeping these limitations in mind, our data suggest that key
elements of the framework of recurrent metastatic melanomas
remain stable with time; as such stability was observed in
eight out of eight patients, it possibly represents the rule rather
than the exception. This is a remarkable finding considering
that at the same time our data also support the accepted view
of late-stage cancer evolution being a highly dynamic process,
also shown recently by others (Gerlinger et al., 2012; Shah
et al., 2012) using indirect computational inference; however,
this study uniquely provides direct evidence by studying
serially asynchronous metastases over a long period.
Our findings suggest that individuality is maintained
throughout a non-directional drift that does not follow a
clearly linear progression, with each metastatic signature
stemming de novo from a stable progenitor entity. Moreover,
there was no sign of a convergent evolution in advanced late-
stage melanoma toward the creation of a convergent lethal
phenotype, and recurrent metastases did not seem to be each
other’s clonal descendants, or accumulate incremental
changes, which is in line with others’ recently published
observations (Colombino et al., 2012).
On the other hand, stable expression of cancer/testis
antigens and the c-kit proto-oncogene across multiple
recurrences of melanoma implies that late-stage melanoma
is capable of displaying stable, case-specific differences
directly affecting markers that determine vulnerability to next
generation immunological or small-molecule biotherapy
(Tyagi et al., 2005; Tyagi and Mirakhur, 2009; Guo et al.,
2011).
It remains to be clarified to what extent these observations
are attributable to the effects of clonal heterogeneity
(Gerlinger et al., 2012; Shah et al., 2012), circulating tumor
cells (Maheswaran et al., 2008; Yu et al., 2011) that may
remain dormant for years and reset the evolutionary clock
upon their reactivation, multiple events of phenotype
switching (Hoek et al., 2008; Eichhoff et al., 2010), or
persistent cancer stem cells opening multiple alternative
ways to cancer evolution with each individual recurrence
(La Porta, 2012; Shakhova and Sommer, 2012). Larger and
more comprehensive studies involving genome-wide DNA
sequencing, epigenetic and proteomic analyses, analyzing
patients with average survival times, and resected whole
tumors instead of cell lines are strongly warranted to clarify
these questions and confirm the applicability of our findings to
usual cases of advanced melanoma.
MATERIALS AND METHODS
Patients and samples
Twenty-six recurrent melanoma metastases were surgically isolated
from eight patients experiencing relapse after one or more successful
treatment intervention(s) with no signs of residual disease. Recurrent
metastases from different tissues appeared in periods spanning
10–148 months, with 8–101 months between recurrences (see
Supplementary Table S1 online for all data regarding samples,
patients, treatments, and disease history). Patients received therapy
and underwent surgery at the Surgery Branch of the National Cancer
Institute, National Institutes of Health, Bethesda, MD, or at the Centro
di Riferimento Oncologico (Italian National Cancer Institute) in
Aviano, Italy. Patients were treated and samples were obtained after
signing written informed consent approved by each institute’s review
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board, and in accordance with the Declaration of Helsinki Principles.
From all lesions, stable cell cultures were established and maintained
at the Department of Transfusion Medicine, Clinical Center, and
National Institutes of Health for at least eight passages. Patients
experiencing recurrent metastases were labeled with capital letters
‘‘A,’’ ‘‘B,’’ ‘‘C,’’ etc., their subsequent metastases were labeled as
‘‘A/1,’’ ‘‘A/2,’’ ‘‘B/1,’’ ‘‘B/2,’’ etc., whereas synchronous metastases
in a given patient were labeled as ‘‘A/1a,’’ ‘‘A/1b,’’ etc. All recurrent
melanoma metastases analyzed appeared after a single primary
tumor. Another 22 melanoma cell lines isolated and maintained as
above were expanded from melanoma patients with rapid disease
course, for whom only one metastasis was available. As no extended
follow-up was possible in these cases, the cell lines are considered
representative of random time points in the natural course of
metastatic melanoma. These cell lines were labeled with Arabic
numbers as ‘‘1,’’ ‘‘2,’’ ’’3,’’ etc.
DNA isolation
Total genomic DNA of cell lines was isolated using the QuickGene
DNA whole-blood kit S and a QuickGene-810 Nucleic Acid Isolation
System (Fujifilm, Tokyo, Japan).
HLA typing
To exclude accidental cross-contamination of samples, low-resolu-
tion HLA typing was performed at the HLA Laboratory, Laboratory
Services Section, Department of Transfusion Medicine, Clinical
Center, National Institutes of Health.
BRAF and NRAS genotyping
PCR was performed from 50-ng genomic DNA using the HotStarTaq
Master Mix Kit (Qiagen, Valencia, CA) and the following primers:
BRAF exon 15 forward—50-TCATAATGCTTGCTCTGATAGGA-30,
BRAF exon 15 reverse—50-GGCCAAAAATTTAATCAGTGGA-30;
NRAS exon 2 forward—50-ATAGCATTGCATTCCCTGTG-30, NRAS
exon 2 reverse—50-CACAAAGATCATCCTTTCAGAGA-30. PCR pro-
ducts were labeled using a Big Dye terminator kit version 3.1 (Life
Technologies, Carlsbad, CA). Sequencing was performed using a
3730 Genetic Analyzer (Life Technologies) and analyzed by the
Sequencher software (Gene Codes, Ann Arbor, MI).
Array comparative genome hybridization
All aCGH studies were conducted using Agilent’s oligo aCGH
platform. Briefly, 1mg of genomic DNA per sample was directly
labeled with a Genomic DNA Enzymatic Labeling Kit, prepared for
hybridization with the help of an Oligo aCGH Hybridization Kit, and
hybridized to 105K Human Genome CGH 105A Oligo Microarrays.
Arrays were washed with Oligo aCGHWash Buffers and scanned in a
High-Resolution Microarray Scanner (all from Agilent, Santa Clara,
CA). Data were deposited in the GEO public database under
GSE38187.
RNA isolation
Total RNA was isolated using Qiagen’s RNEasy Mini Kit, by following
the standard protocol.
GX microarray
For expression array studies, the Affymetrix Gene Array System was
used. Briefly, 250ng of total RNA per sample was amplified using a
WT expression kit. Next, cDNA was labeled with the help of a
GeneChip WT Terminal Label and Control Reactions kit. Samples
were then prepared for hybridization using the GeneChip Hyb
Wash and Stain Kit and loaded to Human Gene ST 1.0 Arrays.
Arrays were washed, phycoerythrin-labeled on a GeneChip Fluidics
Station 450, and loaded into a GeneChip Scanner 3000 7G with
autoloader for scanning (all from Affymetrix, Santa Clara, CA). Data
were submitted to GEO and made publicly available under accession
GSE38187.
Microarray data analysis
Agilent aCGH microarray data were imported into the Partek
Genomics Suite software (Partek, St Louis, MO), quantile-normalized,
and preprocessed using a built-in chromosomal segmentation algo-
rithm (Hawthorn et al., 2010). Individual chromosomal segments
were defined as continuous regions covered by at least 10
consecutive microarray probes, a significant (Po0.001) and
considerable (40.3 copies on average) difference between the CN
of the given segment and neighboring segments, accepting an error
rate of o±0.3 copies. Segmented genomes were subjected to MDS
to describe intersample relationships. Partek’s one-way and two-way
RM ANOVA analyses were performed on segment CNs to identify
CNAs different between individual patients, CNAs consistently
changed in consecutive metastases of the same patient, and CNAs
between recurrent and random cancer samples. To avoid
overestimation of patient-to-patient differences in CNA studies
analyzing a mixed-gender group of patients, X and Y chromosome–
related data were excluded from all such analyses. Significant
differences were identified with a nominal Po0.05 and were
corrected with FDR of o0.05. Homozygous deletions ( / ) were
identified as segments with CNo0.4 at an error rate of o±0.3
copies.
Affymetrix GX data were imported to Partek Genomic Suite (Partek,
St Louis, MO), quantile-normalized, and batch-corrected using dis-
tance-weighted discrimination, as described elsewhere (Benito et al.,
2004). MDS, one-way, and two-way RM ANOVA analyses were
performed as described above. CN and GX data were integrated and
analyzed with help of Partek Genomic Suite. Genes whose expression
levels were found to be affected by CNAs were identified by
computing Pearson’s correlation between CN and GX values. A
Pearson’s correlation of R40.3 with oP0.05 and FDR 0.05 was
accepted as proof for CNA-affected GX.
Flow cytometry
Cells were harvested nonenzymatically using Cellstripper (Corning,
Manassas, VA) and stained with LIVE/DEAD Kit (Life Technologies,
Carlsbad), anti-CD117 (KIT)-APC (BD Biosciences, San Jose, CA) or
isotype controls. Data analysis was performed using a MACSQuant
Analyzer (Miltenyi Biotec, Teterow, Germany) and FlowJo (TreeStar,
Ashland, OR).
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